Program
dexamethasone phosphate
Also written as “Moxidex otic solution”, “Dexamethasone sodium phosphate” and “Dexamethasone Phosphate Ophthalmic Solution”.
Its studies are mostly in Otitis Media · Ataxia Telangiectasia · Peripheral Arterial Disease · Uveitis, Anterior · Cataract, led by 5 companies.
Drug pageDexamethasone phosphate: every studyMany companies study it; this page follows only the 20 they lead. All 66 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eyegate Pharmaceuticalsits history only | 70 open or running | phase 3since May 20, 2010 | Jun 5, 2008 | none ahead |
| Alconits history only | 60 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Quince Therapeuticsits history only | 30 open or running | phase 3since Dec 11, 2023 | Jul 28, 2010 | none ahead |
| Mercator MedSystemsits history only | 20 open or running | phase 4since Nov 4, 2013 | Nov 4, 2013 | none ahead |
| Taiwan Liposomeits history only | 20 open or running | phase 2since Nov 13, 2013 | Nov 13, 2013 | none ahead |
Also a collaborator on its studies: Biotrial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Dec 19, 2007.
- Oct 2, 2008Phase 2 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT00765804 · 89 enrolled · United States
- Feb 18, 2010Phase 3 study in Otitis MediaAlcon · NCT01071902 · 400 enrolled · United States
- May 20, 2010Phase 3 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT01129856 · 198 enrolled · United States
- Jul 28, 2010Quince Therapeutics’ first study: phase 2 study in Colitis, UlcerativeNew to Quince TherapeuticsQuince Therapeutics · NCT01171807 · 33 enrolled · Italy
- Nov 4, 2013Mercator MedSystems’ first study: phase 4 study in Peripheral Arterial DiseaseNew to Mercator MedSystemsMercator MedSystems · NCT01983449 · 285 enrolled · United States
- Nov 13, 2013Taiwan Liposome’s first study: phase 2 study in Macular EdemaNew to Taiwan LiposomeTaiwan Liposome · NCT02006147 · 14 enrolled · Taiwan
- Aug 5, 2015Phase 3 study in Uveitis, AnteriorEyegate Pharmaceuticals · NCT02517619 · 251 enrolled · United States
- Oct 6, 2015Phase 2 study in Patients Having Undergone Unilateral Cataract Extraction and Implantation of a MonofocalEyegate Pharmaceuticals · NCT02571556 · 80 enrolled · United States
- Dec 22, 2015Phase 1 study in VitrectomyEyegate Pharmaceuticals · NCT02644694 · 10 enrolled · United States
- Mar 22, 2017Phase 2 study in Retinal Vein OcclusionTaiwan Liposome · NCT03093701 · 31 enrolled · United States
- Jun 5, 2017Phase 2 study in CataractEyegate Pharmaceuticals · NCT03180255 · 101 enrolled · United States
- May 6, 2019Phase 2 study in Peripheral Arterial DiseaseMercator MedSystems · NCT03942601 · 10 enrolled · United States
- Dec 11, 2023Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06193200 · 105 enrolled · United States, Denmark, Germany and more
- Oct 25, 2024Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06664853 · 101 enrolled · United States, Denmark, Germany and more
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06664853Ataxia Telangiectasia · United States, Denmark, Germany and more | 3 | Terminated | Quince Therapeutics | Jan 30, 2026 | 101 |
| NCT06193200Ataxia Telangiectasia · United States, Denmark, Germany and more | 3 | Completed | Quince Therapeutics | Dec 17, 2025 | 105 |
| NCT03942601Peripheral Arterial Disease · United States | 2 | Terminated | Mercator MedSystems | Apr 30, 2021 | 10 |
| NCT03180255Cataract · United States | 2 | Completed | Eyegate Pharmaceuticals | Nov 7, 2017 | 101 |
| NCT03093701Retinal Vein Occlusion · United States | 2 | Completed | Taiwan Liposome | Feb 4, 2019 | 31 |
| NCT02644694Vitrectomy · United States | 1 | Completed | Eyegate Pharmaceuticals | Oct 2016 | 10 |
| NCT02571556Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal · United States | 2 | Completed | Eyegate Pharmaceuticals | Oct 2016 | 80 |
| NCT02517619Uveitis, Anterior · United States | 3 | Completed | Eyegate Pharmaceuticals | Apr 20, 2018 | 251 |
| NCT02006147Macular Edema · Taiwan | 2 | Completed | Taiwan Liposome | Jul 15, 2020 | 14 |
| NCT01983449Peripheral Arterial Disease · United States | 4 | Completed | Mercator MedSystems | Dec 2016 | 285 |
| NCT01171807Colitis, Ulcerative · Italy | 2 | Completed | Quince Therapeutics | May 15, 2007 | 33 |
| NCT01129856Dry Eye Syndromes · United States | 3 | Completed | Eyegate Pharmaceuticals | Jan 2011 | 198 |
| NCT01071902Otitis Media · United States | 3 | Terminated | Alcon | Oct 2011 | 400 |
| NCT00765804Dry Eye Syndromes · United States | 2 | Completed | Eyegate Pharmaceuticals | Feb 2009 | 89 |
| NCT00750633Otitis Externa | 3 | Completed | Alcon | Jan 2009 | 990 |
| NCT00694135Uveitis, Anterior · United States, India | 2 | Completed | Eyegate Pharmaceuticals | Jul 2009 | 40 |
| NCT00579189Otitis Media | 3 | Completed | Alcon | Jan 2009 | 776 |
| NCT00579020Corneal Diseases · United States | 2 | Terminated | Alcon | Feb 2009 | 144 |
| NCT00578773Otitis Media | 2 | Completed | Alcon | Jan 2009 | 303 |
| NCT00578474Otitis Media | 3 | Completed | Alcon | Aug 2008 | 911 |
How it is read
Names in the registry
- “Moxidex otic solution”, 5 entries
- “Dexamethasone sodium phosphate”, 2 entries
- “Dexamethasone Phosphate Ophthalmic Solution”, 2 entries
- “Low-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
- “High-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
Conditions, from the studies’ own filings
- Otitis Media, 4 studies
- Ataxia Telangiectasia, 2 studies
- Peripheral Arterial Disease, 2 studies
- Uveitis, Anterior, 2 studies
- Cataract, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.